Waters (NYSE:WAT) Stock Unloaded Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Waters Co. (NYSE:WAT). In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Waters stock on April 8th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 4/17/2025.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 4/16/2025.
• Sold $1,001 – $15,000 in shares of Western Digital (NASDAQ:WDC) on 4/11/2025.
• Sold $1,001 – $15,000 in shares of Western Digital (NASDAQ:WDC) on 4/10/2025.
• Sold $1,001 – $15,000 in shares of DexCom (NASDAQ:DXCM) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Invesco (NYSE:IVZ) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Generac (NYSE:GNRC) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Occidental Petroleum (NYSE:OXY) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Pfizer (NYSE:PFE) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of QUALCOMM (NASDAQ:QCOM) on 4/8/2025.

Waters Trading Down 2.0%

WAT opened at $343.73 on Monday. The firm has a 50 day simple moving average of $349.55 and a 200 day simple moving average of $370.42. Waters Co. has a fifty-two week low of $279.24 and a fifty-two week high of $423.56. The company has a market cap of $20.46 billion, a price-to-earnings ratio of 32.09, a price-to-earnings-growth ratio of 3.79 and a beta of 1.14. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.94 and a quick ratio of 0.65.

Waters (NYSE:WAT) last released its earnings results on Tuesday, May 6th. The medical instruments supplier reported $2.25 EPS for the quarter, topping analysts’ consensus estimates of $2.22 by $0.03. The firm had revenue of $661.71 million during the quarter, compared to analyst estimates of $655.50 million. Waters had a net margin of 21.56% and a return on equity of 46.31%. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.21 EPS. On average, sell-side analysts anticipate that Waters Co. will post 12.86 earnings per share for the current year.

Institutional Investors Weigh In On Waters

Several institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Waters by 4.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 415,069 shares of the medical instruments supplier’s stock valued at $152,982,000 after purchasing an additional 16,542 shares during the period. ASR Vermogensbeheer N.V. acquired a new position in shares of Waters during the first quarter worth about $5,769,000. Vanguard Group Inc. grew its holdings in shares of Waters by 2.4% during the first quarter. Vanguard Group Inc. now owns 7,272,252 shares of the medical instruments supplier’s stock worth $2,680,334,000 after buying an additional 173,584 shares in the last quarter. New Age Alpha Advisors LLC acquired a new stake in Waters in the 1st quarter valued at approximately $111,000. Finally, Argent Trust Co lifted its stake in Waters by 27.6% in the 1st quarter. Argent Trust Co now owns 1,282 shares of the medical instruments supplier’s stock valued at $473,000 after acquiring an additional 277 shares in the last quarter. 94.01% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Barclays cut their target price on Waters from $400.00 to $350.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. UBS Group lowered their price target on Waters from $415.00 to $360.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Baird R W raised shares of Waters from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 26th. Sanford C. Bernstein set a $400.00 price objective on shares of Waters and gave the company an “outperform” rating in a report on Wednesday, April 16th. Finally, Scotiabank raised shares of Waters from a “sector perform” rating to a “sector outperform” rating and upped their target price for the company from $430.00 to $450.00 in a research note on Thursday, February 13th. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $390.19.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.